Verona Pharma's Upcoming Financial Disclosure
Verona Pharma plc (NASDAQ: VRNA), a leading biopharmaceutical company, is set to reveal important financial results for the third quarter ended September 30, 2024. The announcement will be made on Monday, November 4, 2024. A pivotal conference call is scheduled for 9:00 a.m. EDT / 2:00 p.m. GMT where executives will discuss the financial outcomes and share key corporate updates.
Joining the Conference Call
Investors and interested participants wishing to join the call can do so by dialing either of the following numbers:
United States Callers
For those located in the United States, please call +1-833-816-1396.
International Callers
International participants can reach out at +1-412-317-0489. Remember to ask for the Verona Pharma call upon connection.
Live Webcast Availability
A live audio webcast of the conference will also be accessible through the Events and Presentations link on the investor section of Verona Pharma's website. Participants will have the chance to access the audio replay of the conference call for a period of 90 days following the event.
Contact Information for Inquiries
For any inquiries regarding the financial results or further information, please reach out to:
Verona Pharma plc
Tel: +1-844-341-9901
Investor Relations
Victoria Stewart, Senior Director of Investor Relations and Communications
Email: IR@veronapharma.com
U.S. Investor Inquiries
Argot Partners
Tel: +1-212-600-1902
Email: verona@argotpartners.com
Media Inquiries
Ten Bridge Communications
Tel: +1-312-523-5016
Email: tbcverona@tenbridgecommunications.com
About Verona Pharma
Verona Pharma is committed to developing innovative therapies aimed at treating chronic respiratory diseases where there is a significant unmet need. Their flagship product, Ohtuvayre™ (ensifentrine), represents a breakthrough as the first inhaled medication that combines bronchodilator and anti-inflammatory properties into a single treatment for COPD. This dual action may extend to other serious respiratory conditions, including chronic bronchiectasis and asthma.
Frequently Asked Questions
When will Verona Pharma announce their Q3 financial results?
Verona Pharma intends to announce their financial results for Q3 on November 4, 2024.
How can I participate in Verona Pharma's conference call?
Participants can join by calling +1-833-816-1396 for U.S. callers or +1-412-317-0489 for international callers.
Where can I find the live webcast of the conference?
The live webcast will be accessible via the Events and Presentations link on Verona Pharma's investor page.
What is Ohtuvayre™?
Ohtuvayre™ (ensifentrine) is Verona Pharma's first product, designed for the maintenance treatment of COPD, combining both bronchodilator and anti-inflammatory effects.
Who can I contact for more information?
You can contact Verona Pharma's investor relations through Victoria Stewart at +1-844-341-9901 or via email at IR@veronapharma.com.